Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Maybe, but consider POLX - they are commercial while waiting FDA - Glyco have a lot of positve data - parallel running is a distinct poss.
Pure conjecture - be nice of the BOD were more forthcoming info wise!
"with associated commercialisation and sales/marketing facilities." for Glycotest this will all depend on trial success, but Proaxsis already has a growing number of products in the commercial/sales phase so, I guess this facility would be of immediate benefit for Proaxsis.
Shared with Proaxis?There is a proactive interview out talking about a liquidity event Q! 2023 on it
Its the "with associated commercialisation and sales/marketing facilities." I find intriguing .
Trial dates moved out to end of 2023, which was somewhat highlighted in the last update from BOD.
As Jimzi highlighted, the US lab setup will aid Glycotest. I do worry a little on how the lab will be financed.
Watching with great interest!
Yes, PI base is very small - quite a few long term inactive holders but given the low share float , [and over 50% II/directors] short term price determine by a few 10% traders - but eventually as NSCI continues to mature, the price will reflect its potential ..
The power of the herd - if we were AVCT and the associated twitter / BB following, we would be currently at £1.3 - but for the moment v- as per the number of posts here - we wait for imminent news on key investments.
The other problem is that although WH Ireland reiterate its £1.8 per share value - it does not give the market a thorough proper report to support it so no one takes any notice and the BOD, whilst very competent, do not seem to want to up its PR atm.
May be this will change soon
Again today PDSB is above $9 / share = £10.2mio value for NSCI. Yet the share price can't seem to get above 65-70p.
Theory: placement on 22nd June was at 67p, hung around there for 2 months then went below 50p and now recovering again. Can't help but think some of those who bought in the placement and were underwhelmed at the subsequent performance are just happy to get out where they bought which is why there is so much selling here.
At the lows on NSCI (42.5p) = mkt cap £10mio, PDSB was around $3/shr so made up £3.4mio of NSCI mkt cap. Since then stake in PDSB has increased in value by £6.8mio to £10.2mio, and NSCI (using a 70p price now) has increased to just £16.3mio so only by £6.3mio.
So even if at the lowest ebb of NSCI, the rest of the portfolio is unchanged in value, we should be at least 72p. Let's see what happens once the selling at this level is exhausted, but fundamentally the main problem is that not enough people know about this share and are interested in even looking at the value here.
"Both Glycotest and ProAxsis have an immediate need for a US lab, with associated commercialisation and sales/marketing facilities. Temporary space has already been secured, close to Washington DC and plans are well advanced for suitable leased premises."
December is close
From the Glycotest presentation
• Huge and growing populations with viral and non-viral hepatitis—driving progressive fibrosis, liver cancer risk and need for effective disease surveillance
o Cost effective HCC panel will enable early-stage HCC detection, lower cost treatment options, and better patient outcomes that will drive market adoption
• Estimated market value for the HCC Panel is $818 MM PA in the US alone
• Assumes only 620,000 US patients under surveillance—20% of 3.1 MM eligible patients
• In China…
• > 350,000 people die of liver cancer each year
• > 350MM people at risk for liver cancer due to serious liver disease—viral hepatitis, fatty liver disease and NASH, alcoholic liver disease and ASH
Top three liver disease countries are PRC, US and Japan. All three markets protected by patents – as is the EU.
So US market is $800m [above]
China has 5 times the US pop. Market size? Glyco receives 6% of gross sales – all net profit
Japan – half US pop – market size?
EU etc.
Run some figures based on the above with varying uptake at 55% GP [Edison] ex PRC which is full net profit on 6% gross sales for 15 years [
The cross holding with Fosan with the royalty is a masterstroke of accessing a huge market you otherwise would not penetrate. Proper management
At £12m for PDS now, undervalued doesn't come close.
Price being almost placing price -set by insiders - time methinks to increase exposure
Pdsb up over 20% today ;-)
All looking good here.
News from some of other investments companies is due I.e. Proaxsis.
Sofant have been quite since the order from the European space agency.
I will do a bit of digging around to see if there is anything out there on the various investments.
sellers probably mms trying to suppress the sp
selling and we are up £1m in one hour lol
There are in fact fewer than 30 million shares currently in issue.
The figure is 28,458,701.
At the time of this post over 16 million traded today.
My prediction it will take off before the close looks to be mistaken.
However I think the free float is reducing, as larger investors take a position.
https://mrkts.com/stocks/healthcare/geode-capital-slowly-builds-position-in-pdsb-stock/
NSCI hold approximately 4.7% of PDS.
Today following further good news from PDS it's share price is up.
However it is the volume of PDS shares traded so far, which is of interest.
There are approximately 30 million PDS shares in issue and we are approaching
10 million shares traded with almost 5 hours before close of trade.
So almost a third traded.
My thought is that an institution is taking a major stake - it's brokers
are selling large quantities, whilst also buying.
In order to fill the order, at as low a price as possible.
If I am right the share price will really take off as we reach
the end of trading in New York.
Thank you that is an incredibly useful post.
Well some nice results out of PDSB today, share price +25% to $7 in pre-market trading.
NSCI own (I think) 4.7% of PDSB which equates to about £8mio if it stays at $7/share.
[PDSB float is 28.46m shares x $7 *4.7% / FX rate of 1.18]
This is over 60% of NSCI's market cap at Friday's close, or 50% of NSCI's market cap at 70p where it has traded today.
Maybe the rocket needed to make people take notice? Would be nice to see this back to £1
Nothing new but Glycotest gets a mention.
https://twitter.com/hazeldomingopa/status/1588899265023455233?s=46&t=ANoM3Mj5ccti1AhHX_UJYQ
Glycotest is still the unicorn for me. If it goes commercial, it will be very significant.
My money is on PDSB being taken out at $20+ before xmas.